KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Dividends payables (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Dividends payables for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Dividends payables rose 7.13% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 7.13% year-over-year, with the annual reading at $1.1 billion for FY2025, 7.13% up from the prior year.
  • Dividends payables hit $1.1 billion in Q4 2025 for Abbott Laboratories, up from $1.0 billion in the prior quarter.
  • In the past five years, Dividends payables ranged from a high of $1.1 billion in Q4 2025 to a low of $797.0 million in Q3 2021.
  • Historically, Dividends payables has averaged $914.2 million across 5 years, with a median of $887.5 million in 2022.
  • Biggest five-year swings in Dividends payables: grew 25.75% in 2021 and later grew 2.87% in 2022.
  • Year by year, Dividends payables stood at $831.0 million in 2021, then rose by 6.74% to $887.0 million in 2022, then grew by 7.67% to $955.0 million in 2023, then grew by 7.23% to $1.0 billion in 2024, then rose by 7.13% to $1.1 billion in 2025.
  • Business Quant data shows Dividends payables for ABT at $1.1 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.